Physician profile
Jesse Cabiling
NPI 1790443521
$1,737.59
in general payments reported to CMS, 2019-2025
22 companies · $609 in 2025
The $609 reported for 2025 was more than what 76% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $484 · 2024: $424 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.64 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $419.28 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $224.07 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Alexion Pharmaceuticals, INC. | $153.84 | 2023-2025 | Ultomiris |
| Seagen INC. | $99.99 | 2024 | |
| Daiichi Sankyo INC. | $91.02 | 2023-2024 | Injectafer, Vanflyta |
| Genzyme Corporation | $87.38 | 2022-2024 | |
| Amgen INC. | $77.88 | 2022-2023 | Nplate, Xgeva |
| Sobi, INC | $73.57 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $71.06 | 2025 | Keytruda |
| Tersera Therapeutics LLC | $65.38 | 2025 | Xermelo |
| Jazz Pharmaceuticals INC. | $54.73 | 2022-2023 | |
| Shield Therapeutics INC | $49.23 | 2024-2025 | |
| Stemline Therapeutics INC. | $45.91 | 2025 | Orserdu |
| Celgene Corporation | $43.91 | 2022-2023 | Pomalyst |
| Ipsen Biopharmaceuticals, INC | $26.07 | 2025 | Onivyde |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $24.48 | 2025 | |
| Janssen Biotech, INC. | $24.19 | 2023 | Rybrevant |
| Melinta Therapeutics, LLC | $23.99 | 2025 | Rezzayo |
| Astellas Pharma US INC | $23.66 | 2025 | Vyloy |
| Syndax Pharmaceuticals, INC. | $20.59 | 2025 | Revuforj |
| Immunocore Limited | $18.93 | 2023 | Kimmtrak |
| Bayer Healthcare Pharmaceuticals INC. | $18.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Cabiling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.